12:00 AM
 | 
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TPI 287: Phase I started

Cortice said investigators at the University of California, San Francisco, began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate 2, 6.3 and 20 mg/m 2 IV TPI 287 once every 3 weeks for 9...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >